The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach (TAPIR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01940094|
Recruitment Status : Recruiting
First Posted : September 11, 2013
Last Update Posted : October 12, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Granulomatosis With Polyangiitis||Drug: 5 mg Prednisone Drug: 0 mg Prednisone||Phase 3|
Patients with granulomatosis with polyangiitis (GPA, Wegener's) will be recruited at one of the Vasculitis Centers of Excellence. Participants will be randomized 1:1 either to taper their prednisone dose down to 5 mg/day according to a standardized schedule and stay at 5 mg/day of prednisone for the duration of the study or until a study endpoint, or taper their prednisone dose down to 0 mg/day using a standard schedule and stay at 0 mg/day for the duration of the study or until a study endpoint. All study participants will be followed for 6 months (from reaching a prednisone dose of 5 mg/day) or until an increase of prednisone dose (after randomization) occurs, whichever comes first.
Participants will have up to four study visits, a screening visit (visit 1), a baseline (visit 2), a month 3 visit (visit 3) and a month 6 or flare visit (visit 3) and up to two follow-up phone calls from the study coordinator at randomization and at month 1 (randomization and 1 month phone call may be combined if randomization occurs at month 1).
This study is a project of the Vasculitis Clinical Research Consortium (VCRC) funded through the National Institutes of Health Rare Diseases Clinical Research Network (RDCRN) with the purpose of promoting vasculitis research. The VCRC is the major clinical research infrastructure in North America for the study of vasculitis, and eight VCRC Centers of Excellence will be recruiting for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||159 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach|
|Actual Study Start Date :||February 2014|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||December 2023|
Experimental: 5 mg Prednisone
Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
Drug: 5 mg Prednisone
Subjects will remain on daily prednisone dose of 5 mg
Experimental: 0 mg Prednisone
Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
Drug: 0 mg Prednisone
Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
- Physician decision to increase glucocorticoids for disease relapse. [ Time Frame: Six months ]
- Time to disease flare. [ Time Frame: 6 months ]
- Safety outcomes. [ Time Frame: 6 months ]Rate and type of serious adverse events and infections.
- Protocol performance at VCRC Centers of Excellence. [ Time Frame: 6 months ]Evaluation of patient characteristics, protocol compliance, participant retention, data completeness, timeliness of data entry, and data accuracy.
- Health-related quality of life survey [ Time Frame: Measured at baseline and end of the study ]Patient Reported Outcomes Measurement Information System (PROMIS) Assessment
- Health-related quality of life surveys [ Time Frame: Measured at baseline and the end of the study ]Measured by Short Form-36
- Health-related quality of life surveys [ Time Frame: Measured at baseline, month 3, and end of the study ]Measured by a Patient Global Assessment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Established diagnosis of granulomatosis with polyangiitis (GPA) where patients will need to meet at least 2 of the 5 for the classification of GPA, at least one of which must be criterion d or e:
The modified American College of Rheumatology (ACR) criteria are:
A. Nasal or oral inflammation, defined as the development of painful or painless oral ulcers or purulent or bloody nasal discharge.
B. Abnormal chest radiograph, defined as the presence of nodules, fixed infiltrates, or cavities.
C. Active urinary sediment, defined as microscopic hematuria (>5 red blood cells per high power field) or red blood cell casts.
D. Granulomatosis inflammation on biopsy, defined as histologic changes showing granulomatous inflammation within the wall of an artery or in the perivascular or extravascular area. Note: Pauci-immune glomerulonephritis seen on kidney biopsy will suffice for this criterion.
E. Positive anti-neutrophil cytoplasmic antibody (ANCA) test specific for proteinase-3 measures by enzyme-linked immunoassay.
Patients who are myeloperoxidase (MPO) positive or ANCA negative are still eligible for this study if they meet the criteria above and are felt to have GPA.
- Active disease within the prior 12 months (initial presentation or relapse) that at time of active disease required treatment with prednisone >20 mg/day.
- Disease remission at time of enrollment.
- Prednisone dose at time of enrollment of ≥ 5 mg/day and ≤ 20 mg/day.
- Participant age of 18 years or greater.
- If the patient is taking an immunosuppressive medication agent other than prednisone (maintenance agent) then the maintenance agent must be at a stable dose for one month prior to enrollment with no plans by the treating physician to change the dose (other than for safety purposes/toxicity) for the duration of the study (through the month 6 visit or early termination). Acceptable maintenance agents include azathioprine, leflunomide, 6-mercaptopurine, methotrexate, mycophenolate mofetil, mycophenolate sodium, or rituximab. Patients may be on trimethoprim/sulfamethoxazole (TMP/SMX) for use as either a maintenance agent or for prophylaxis for infection. TMP/SMX may be used in combination with other drugs.
6.1 If the patient is regularly taking trimethoprim/sulfamethoxazole at any dose then the patient is eligible if there no plans by the treating physician to change the dose after enrollment (other than dose reduction or discontinuation for safety purposes/toxicity) for the duration of the study.
1. Comorbid condition that has moderate likelihood of requiring a course of prednisone within one year of enrollment (e.g. chronic obstructive pulmonary disease (COPD), asthma, adrenal insufficiency).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01940094
|Contact: Carol McAlear, MAemail@example.com|
|United States, Kansas|
|University of Kansas Medical Center||Recruiting|
|Kansas City, Kansas, United States, 66160|
|Contact: Theresa Howard firstname.lastname@example.org|
|United States, Massachusetts|
|Brigham and Women's Hospital||Completed|
|Boston, Massachusetts, United States, 02215|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Michael Stachowitz email@example.com|
|Principal Investigator: Ulrich Specks, MD|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Contact: Hannah Thome THOMEH@ccf.org|
|Principal Investigator: Carol A Langford, MD, MHS|
|United States, Pennsylvania|
|University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Sarah Gillespie Sarah.Hopkins@Pennmedicine.upenn.edu|
|Principal Investigator: Peter A Merkel, MD, MPH|
|University of Pittsburgh||Completed|
|Pittsburgh, Pennsylvania, United States, 15261|
|United States, Utah|
|University of Utah||Completed|
|Salt Lake City, Utah, United States, 84112|
|St. Joseph's Healthcare||Recruiting|
|Hamilton, Ontario, Canada|
|Contact: Sandra Messier firstname.lastname@example.org|
|Principal Investigator: Nader Khalidi, MD|
|Mount Sinai Hospital||Recruiting|
|Toronto, Ontario, Canada, M5T 3L9|
|Contact: Suneet Khurana Suneet.Khurana@sinaihealth.ca|
|Principal Investigator: Christian Pagnoux, MD|
|Principal Investigator:||Peter A Merkel, MD, MPH||University of Pennsylvania|
|Principal Investigator:||Jeffery P Krischer, PhD||University of South Florida|
|Responsible Party:||Peter Merkel, Chief, Division of Rheumatology, Professor of Medicine and Epidemiology, University of Pennsylvania|
|Other Study ID Numbers:||
R01HL115041 ( U.S. NIH Grant/Contract )
U54AR057319 ( U.S. NIH Grant/Contract )
|First Posted:||September 11, 2013 Key Record Dates|
|Last Update Posted:||October 12, 2022|
|Last Verified:||October 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Granulomatosis with polyangiitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Granulomatosis with Polyangiitis
Lung Diseases, Interstitial
Respiratory Tract Diseases
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal